DE60331219D1 - Azaindole als hemmstoffe von c-jun n-terminalen kinasen - Google Patents

Azaindole als hemmstoffe von c-jun n-terminalen kinasen

Info

Publication number: DE60331219D1
Authority: DE; Germany
Prior art keywords: jun; azaindole; terminal; kinasen; inhibitors
Prior art date: 2002-03-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE60331219T

Other languages

English (en)

Inventor

Piotr Graczyk

Hirotoshi Numata

Gurpreet Bhatia

Darren P Medland

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai R&D Management Co Ltd

Original Assignee

Eisai R&D Management Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2003-03-17

Publication date

2010-03-25

2002-03-28 Priority claimed from GB0207488A external-priority patent/GB0207488D0/en

2003-01-08 Priority claimed from GB0300400A external-priority patent/GB0300400D0/en

2003-03-17 Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd

2010-03-25 Application granted granted Critical

2010-03-25 Publication of DE60331219D1 publication Critical patent/DE60331219D1/de

2023-03-18 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE60331219T 2002-03-28 2003-03-17 Azaindole als hemmstoffe von c-jun n-terminalen kinasen Expired - Fee Related DE60331219D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB0207488A GB0207488D0 (en)	2002-03-28	2002-03-28	Inhibitors
GB0300400A GB0300400D0 (en)	2003-01-08	2003-01-08	JNK inhibitors
PCT/GB2003/001115 WO2003082869A1 (en)	2002-03-28	2003-03-17	Azaindoles as inhibitors of c-jun n-terminal kinases

Publications (1)

Publication Number	Publication Date
DE60331219D1 true DE60331219D1 (de)	2010-03-25

Family

ID=28676497

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60331219T Expired - Fee Related DE60331219D1 (de)	2002-03-28	2003-03-17	Azaindole als hemmstoffe von c-jun n-terminalen kinasen

Country Status (11)

Country	Link
US (1)	US7291630B2 (de)
EP (1)	EP1490365B1 (de)
JP (1)	JP2005534619A (de)
KR (1)	KR20050013534A (de)
CN (1)	CN100338062C (de)
AT (1)	ATE457312T1 (de)
AU (1)	AU2003214414B2 (de)
CA (1)	CA2479205A1 (de)
DE (1)	DE60331219D1 (de)
IL (1)	IL164082A0 (de)
WO (1)	WO2003082869A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0108770D0 (en)	2001-04-06	2001-05-30	Eisai London Res Lab Ltd	Inhibitors
ATE457312T1 (de)	2002-03-28	2010-02-15	Eisai R&D Man Co Ltd	Azaindole als hemmstoffe von c-jun n-terminalen kinasen
EP1490364B1 (de)	2002-03-28	2007-09-26	Eisai R&D Management Co., Ltd.	7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
GB0305142D0 (en)	2003-03-06	2003-04-09	Eisai London Res Lab Ltd	Synthesis
JP4787150B2 (ja) *	2003-03-06	2011-10-05	エーザイ・アール・アンド・ディー・マネジメント株式会社	Ｊｎｋ阻害剤
US7612086B2 (en)	2003-05-16	2009-11-03	Eisai R & D Management Co. Ltd.	JNK inhibitors
ES2527118T3 (es)	2003-12-19	2015-01-20	Plexxikon Inc.	Compuestos y procedimientos de desarrollo de moduladores de Ret
GB0405055D0 (en) *	2004-03-05	2004-04-07	Eisai London Res Lab Ltd	JNK inhibitors
AU2005236002A1 (en)	2004-04-02	2005-11-03	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of rock and other protein kinases
US7498342B2 (en)	2004-06-17	2009-03-03	Plexxikon, Inc.	Compounds modulating c-kit activity
CA2572058A1 (en) *	2004-06-30	2006-01-12	Vertex Pharmaceuticals Incorporated	Azaindoles useful as inhibitors of protein kinases
US7361764B2 (en)	2004-07-27	2008-04-22	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
CA2573362A1 (en)	2004-07-27	2006-02-09	Sgx Pharmaceuticals, Inc.	Pyrrolo-pyridine kinase modulators
US7626021B2 (en)	2004-07-27	2009-12-01	Sgx Pharmaceuticals, Inc.	Fused ring heterocycle kinase modulators
EP1778687A2 (de)	2004-07-27	2007-05-02	SGX Pharmaceuticals, Inc.	Heterocyclen mit kondensiertem ring als kinase-modulatoren
AU2005302707A1 (en) *	2004-10-27	2006-05-11	Janssen Pharmaceutica N.V.	Pyridine imidazoles and aza-indoles as progesterone receptor modulators
NZ563444A (en)	2005-05-17	2011-04-29	Plexxikon Inc	Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
AU2006251832A1 (en)	2005-05-27	2006-11-30	Queen's University At Kingston	Treatment of protein folding disorders
KR101125919B1 (ko)	2005-06-22	2012-06-12	플렉시콘, 인코퍼레이티드	단백질 키나제 억제제로서의 피롤로［2,3-ｂ］피리딘 유도체
GB0516156D0 (en)	2005-08-05	2005-09-14	Eisai London Res Lab Ltd	JNK inhibitors
CN101448827A (zh) *	2006-05-22	2009-06-03	阿斯利康(瑞典)有限公司	吲哚衍生物
JP4857071B2 (ja) *	2006-10-12	2012-01-18	潤平笹部	筋萎縮性側策硬化症（ａｌｓ）の検出方法
EP2081892A4 (de) *	2006-11-17	2014-03-05	Donald F Weaver	Verbindungen und verfahren zur behandlung von proteinfaltungserkrankungen
WO2008063888A2 (en)	2006-11-22	2008-05-29	Plexxikon, Inc.	Compounds modulating c-fms and/or c-kit activity and uses therefor
EP2170830B1 (de)	2007-07-17	2014-10-15	Plexxikon, Inc.	2-FLUORO-BENZOSULFONAMID-VERBINDUNGEN ALS Raf-KINASE-MODULATOREN
KR20170058465A (ko)	2009-04-03	2017-05-26	에프. 호프만-라 로슈 아게	프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
BR112012012156A2 (pt)	2009-11-06	2015-09-08	Plexxikon Inc	compostos e métodos para modulação de cinase, e indicações para esta
WO2011109932A1 (en)	2010-03-09	2011-09-15	F.Hoffmann-La Roche Ag	Novel process for the manufacture of 5-halogenated-7-azaindoles
MY162950A (en)	2011-02-07	2017-07-31	Plexxikon Inc	Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es)	2011-02-21	2013-09-18	Plexxikon Inc	Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
US9150570B2 (en)	2012-05-31	2015-10-06	Plexxikon Inc.	Synthesis of heterocyclic compounds
ES2706399T3 (es)	2013-02-04	2019-03-28	Janssen Pharmaceutica Nv	Moduladores de FLAP
TWI644899B (zh) *	2013-02-04	2018-12-21	健生藥品公司	Ｆｌａｐ調節劑
SI2970265T1 (sl) *	2013-03-15	2018-10-30	Plexxikon Inc.	Heterociklične spojine in njihova uporaba
US20140303121A1 (en)	2013-03-15	2014-10-09	Plexxikon Inc.	Heterocyclic compounds and uses thereof
US9206188B2 (en) *	2013-04-18	2015-12-08	Arrien Pharmaceuticals Llc	Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2015089192A1 (en) *	2013-12-11	2015-06-18	Quanticel Pharmaceuticals, Inc.	Inhibitors of lysine specific demethylase-1
US9758505B2 (en)	2014-02-12	2017-09-12	Iteos Therapeutics	3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use
CA2948842C (en)	2014-05-15	2019-09-24	Iteos Therapeutics	Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors
CN107635990A (zh)	2015-03-17	2018-01-26	辉瑞公司	新型3‑吲哚取代的衍生物、药物组合物及使用方法
CA2994917A1 (en)	2015-08-10	2017-02-16	Pfizer Inc.	3-indol substituted derivatives, pharmaceutical compositions and methods for use
WO2018167147A1 (en) *	2017-03-15	2018-09-20	F. Hoffmann-La Roche Ag	Azaindoles as inhibitors of hpk1
JP7675519B2 (ja)	2017-10-13	2025-05-13	オプナバイオソシエテアノニム	キナーゼを調節するための化合物の固体形態

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI922347L (fi) *	1990-01-05	1992-05-22	Pfizer	Azaoxindolderivat.
MX9305947A (es) *	1992-09-29	1994-06-30	Smithkline Beecham Plc	Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
GB9226855D0 (en) *	1992-12-23	1993-02-17	Erba Carlo Spa	Vinylene-azaindole derivatives and process for their preparation
CA2192820C (en) *	1994-06-16	2000-11-28	Yuhpyng L. Chen	Pyrazolo and pyrrolopyridines
FR2732969B1 (fr)	1995-04-14	1997-05-16	Adir	Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9721437D0 (en)	1997-10-10	1997-12-10	Glaxo Group Ltd	Heteroaromatic compounds and their use in medicine
ES2301255T3 (es)	1998-12-17	2008-06-16	F. Hoffmann-La Roche Ag	4,5-pirazinaxindoles como inhibidores de proteinoquinasas.
CA2354591A1 (en)	1998-12-17	2000-06-22	F. Hoffmann-La Roche Ag	4-aryloxindoles as inhibitors of jnk protein kinases
GB9904933D0 (en)	1999-03-04	1999-04-28	Glaxo Group Ltd	Compounds
AR028475A1 (es) *	1999-04-22	2003-05-14	Wyeth Corp	Derivados de azaindol y uso de los mismos para la manufactura de un medicamento para el tratamiento de la depresion.
KR20080028516A (ko)	1999-08-19	2008-03-31	시그널 파머슈티컬스 인크	Ｊｎｋ억제제로서의 피라졸로안트론과 그 유도체 및 이를함유하는 조성물
EP1106621B1 (de)	1999-12-07	2003-11-19	Fuji Photo Film Co., Ltd.	Fluoreszente materialen
WO2001047922A2 (en)	1999-12-24	2001-07-05	Aventis Pharma Limited	Azaindoles
CA2396257A1 (en) *	2000-01-06	2001-07-12	Merck Frosst Canada & Co./Merck Frosst Canada & Cie	Novel compounds and compositions as protease inhibitors
PE20020506A1 (es)	2000-08-22	2002-07-09	Glaxo Group Ltd	Derivados de pirazol fusionados como inhibidores de la proteina cinasa
GB0108770D0 (en)	2001-04-06	2001-05-30	Eisai London Res Lab Ltd	Inhibitors
ATE457312T1 (de)	2002-03-28	2010-02-15	Eisai R&D Man Co Ltd	Azaindole als hemmstoffe von c-jun n-terminalen kinasen

2003
- 2003-03-17 AT AT03709986T patent/ATE457312T1/de not_active IP Right Cessation
- 2003-03-17 CA CA002479205A patent/CA2479205A1/en not_active Abandoned
- 2003-03-17 JP JP2003580334A patent/JP2005534619A/ja active Pending
- 2003-03-17 EP EP03709986A patent/EP1490365B1/de not_active Expired - Lifetime
- 2003-03-17 US US10/509,127 patent/US7291630B2/en not_active Expired - Fee Related
- 2003-03-17 IL IL16408203A patent/IL164082A0/xx unknown
- 2003-03-17 WO PCT/GB2003/001115 patent/WO2003082869A1/en active Application Filing
- 2003-03-17 CN CNB038095696A patent/CN100338062C/zh not_active Expired - Fee Related
- 2003-03-17 KR KR10-2004-7015414A patent/KR20050013534A/ko not_active Ceased
- 2003-03-17 DE DE60331219T patent/DE60331219D1/de not_active Expired - Fee Related
- 2003-03-17 AU AU2003214414A patent/AU2003214414B2/en not_active Ceased

Also Published As

Publication number	Publication date
US7291630B2 (en)	2007-11-06
KR20050013534A (ko)	2005-02-04
CA2479205A1 (en)	2003-10-09
EP1490365A1 (de)	2004-12-29
CN100338062C (zh)	2007-09-19
EP1490365B1 (de)	2010-02-10
JP2005534619A (ja)	2005-11-17
AU2003214414A1 (en)	2003-10-13
ATE457312T1 (de)	2010-02-15
US20060111390A1 (en)	2006-05-25
CN1649869A (zh)	2005-08-03
WO2003082869A1 (en)	2003-10-09
IL164082A0 (en)	2005-12-18
AU2003214414B2 (en)	2008-10-09

Publication	Publication Date	Title
DE60331219D1 (de)	2010-03-25	Azaindole als hemmstoffe von c-jun n-terminalen kinasen
ATE374200T1 (de)	2007-10-15	7-azaindole als inhibitoren c-jun n-terminaler kinasen zur behandlung neurodegenerativer störungen
ATE297394T1 (de)	2005-06-15	Jun kinase inhibitoren
ATE468337T1 (de)	2010-06-15	3,5-disubstituierte 1h-pyrrolo ä2,3-bü pyridine als jnk-inhibitoren
WO2004078756A3 (en)	2005-03-24	Jnk inhibitors
ATE486870T1 (de)	2010-11-15	Jnk inhibitoren
WO2004101565A3 (en)	2005-02-03	Jnk inhibitors
ATE530540T1 (de)	2011-11-15	Pyrimidonverbindungen als gsk-3-inhibitoren
PL1660507T5 (pl)	2017-12-29	Inhibitory proteazomu oraz sposoby ich stosowania
NO20052888L (no)	2005-08-12	Diamintriazoler anvendelige som inhibitorer av proteinkinaser
NO20064852L (no)	2006-10-24	Azaindoler som er nyttige som inhibitorer av jak og andre proteinkinaser
NO20072567L (no)	2007-07-17	Triazoler nyttige som proteinkinase-inhibitorer
ATE451369T1 (de)	2009-12-15	Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
EP1841770A4 (de)	2009-03-04	Bicyclische pyrimidine als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
NO20070049L (no)	2007-01-30	Pyrrolotriazinderivater anvendelig for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20074634L (no)	2007-10-31	Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20061194L (no)	2006-05-05	Mitotiske kinesininbibitorer
DE602004025504D1 (de)	2010-03-25	Bicyclische heterocyclische p-38-kinase-inhibitoren
DK1846424T3 (da)	2010-05-17	Proteasom-inhibitorer og fremgangsmåder til anvendelse deraf
NO20071078L (no)	2007-04-26	Antivirale forbindelser
EA200870380A1 (ru)	2009-02-27	Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
NO20080150L (no)	2008-03-10	Inhibitorer av AKT-aktivitet
CY1108146T1 (el)	2014-02-12	ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ β-ΑΜΙΝΟ-ΕΤΕΡΟΚΥΚΛΙΚΗΣ-ΔΙΠΕΠΤΙΔΥΛΙΚΗΣ ΠΕΠΤΙΔΑΣΗΣ ΓΙΑ ΤΗΝ ΑΓΩΓΗ Ή ΠΡΟΛΗΨΗ ΤΟΥ ΔΙΑΒΗΤΗ
ATE423087T1 (de)	2009-03-15	Proteasome inhibitoren und deren verwendung
NO20071005L (no)	2007-05-16	Enantiomerer av selekterte kondenserte pyrimidoner og anvendelser for behandling og forebygging av cancer

Legal Events

Date	Code	Title	Description
2011-01-20	8339	Ceased/non-payment of the annual fee